INTRODUCTION
============

Probiotic research faces new challenges. Currently, there is an increased legislative pressure, in both the EU and the USA, to strictly limit the health communications of probiotics. While a more strict regulation is of course not a major problem as such, it may considerably hamper the release of new probiotic strains and applications. This is especially worrisome, as the boost of the metagenomics research efforts starts to pay off by creating numerous new and interesting working hypothesis for microbiota manipulation in maintaining and restoring health. Results of this research, for the first time, allow to avoid the tedious screening of large numbers of strains and to identify potential new health promoting bacteria from the comparison of population with different health status (lean versus obese, allergic versus non-allergic, etc.). Several new applications have been suggested already either via a supplemented diet or via a pharmaceutical approach. Improving *Faecalibacterium prausnitzii* levels has been suggested as beneficial for inflammatory bowel disease (IBD) patients ([@B198]), the use of *Akkermansia muciniphila* has recently been patented for treating metabolic disorders ([@B33]) and the role of dietary bioactive proteins and peptides in autism spectrum disorders may also result in new probiotic strains in the market ([@B252]). The legislative framework today is not ready to cope with these new applications. Approval will require a full analysis of the mechanism of action. A full inventory of the risks will have to be determined in different populations, at different doses and using different delivery modes and matrices. The research approaches presented in this review aim to assist in this process. While many of the *in vitro* models described here may seem outdated, they are still used for cost and ethical reasons. The use of new molecular omics-based technologies is increasing fast and it will most probably replace traditional screening methods. Omics technologies may also turn out to be very effective in the follow-up analysis of probiotic candidate strains resulting from *in vitro* and/or *in vivo* screening with current methodologies. Genome sequencing, as an example, will allow to quickly detect and eliminate strains that pose a potential risk, through the presence of antibiotic resistance or virulence genes. The new research approaches will also facilitate the analysis and description of functional mechanisms, facilitating the construction of health claim or pharmaceutical dossiers. Another consequence of this focus on mechanisms might be that live microorganisms will no longer be necessary, but they will be replaced by the active ingredients or metabolites identified as the active compound. This might cause a shift for certain applications from the food to the pharma area. However, it remains to be shown if this shift will also result in active ingredients that have no side effects, as it is currently expected from probiotics. The use of the models and research strategies described in this review, alone or in combination, may help to answer that type of questions.

DOCUMENTING PROBIOTICS WITH *IN VITRO* ASSAYS
=============================================

SURVIVING STRESS WITHIN THE HOST
--------------------------------

Since the early days of probiotics research, *in vitro* screening of probiotics was a preferable choice due to the simplicity and the low cost of such approaches (**Table [1](#T1){ref-type="table"}**). Even though some of these tests may seem outdated they are still in use and they can be found in recent reports. Perhaps the most important advantage of *in vitro* assays is their ability to screen multiple strains simultaneously.

###### 

*In vitro* assays employed during screening for novel probiotic strains.

  Probiotic property                 Assays                                                                                                                                                                        Representative references
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Surviving stress within the host   Low pH and bile (e.g., artificial gastric and pancreatic juices and GIT simulators)                                                                                           [@B54], [@B200], [@B187], [@B40], [@B197], [@B183], [@B165], [@B24], [@B55], [@B278]
  Safety assays                      Antibiotic resistance                                                                                                                                                         [@B64], [@B7], [@B220]
                                     Hemolytic activity                                                                                                                                                            [@B220]
                                     Adhesion to mammalian cells                                                                                                                                                   [@B116]
                                     Production of enzymes (e.g., glycosidases)                                                                                                                                    [@B210], [@B18]
                                     Production of toxins (e.g., cytolysins)                                                                                                                                       [@B263]
                                     Production of biogenic amines                                                                                                                                                 [@B111], [@B25]
  Colonization of the host           Cell surface hydrophobicity                                                                                                                                                   [@B214], [@B287], [@B142], [@B132], [@B98]
                                     Adhesion to mucus (e.g., adhesion to mucin, enzymatic activity of GAPDH)                                                                                                      [@B151], [@B164], [@B84], [@B150]
                                     Auto-aggregation screening                                                                                                                                                    [@B48], [@B12], [@B184], [@B23]
                                     Adhesion to intestinal epithelium (e.g., cell-lines, tissue fragments and whole tissue models)                                                                                [@B284], [@B205], [@B264]
  Antimicrobial assays               Production of antimicrobial metabolites such as organic acids and bacteriocins (e.g., simple inhibition tests, turbidometric assays, bioluminescence assay, streak methods)   [@B262], [@B131], [@B258], [@B162], [@B218], [@B110], [@B117], [@B163], [@B44], [@B59], [@B143], [@B3], [@B51]
                                     Co-aggregation with pathogens                                                                                                                                                 [@B49], [@B12]
                                     Enhancement of intestinal barrier function (e.g., TER measurement, immunofluorescence of tight junction protein antibodies, tight junctional protein phosphorylation)         [@B228], [@B304], [@B77]
  Immunomodulation                   Bacterial translocation in the GIT                                                                                                                                            [@B57]
                                     Co-culture models mimicking *in vivo* situation (e.g., co-culture models or three component models with epithelium cells, immune cells and bacteria)                          [@B21], [@B37]
                                     Interaction of host immune system with bacterial compounds (e.g., lipoteichoic acids and peptidoglycan)                                                                       [@B196], [@B57], [@B257]
                                     Regulation of epithelial tight junctions                                                                                                                                      [@B193]
                                     Anti-inflammatory immune-stimulating properties (e.g., alleviation of IBD and allergic symptoms)                                                                              [@B93], [@B254], [@B89]
                                     β-Hexosaminidase release assay (alleviation of allergic reactions)                                                                                                            [@B148]
  Cardiovasular diseases             Deconjugation of bile salts (e.g., BSH activity)                                                                                                                              [@B61], [@B253], [@B302]
                                     Conversion of cholesterol to coprostanol                                                                                                                                      [@B179]
                                     Peptides from bacterial metabolism with ACE inhibitory activity                                                                                                               [@B216]
  Anticancer                         Ames test                                                                                                                                                                     [@B29]
                                     Comet assay                                                                                                                                                                   [@B223]
                                     Nitrosamine degrading assay                                                                                                                                                   [@B68]
                                     Preventing colon cancer cell invasion                                                                                                                                         [@B45]
                                     Induction of apoptosis of cancer cells                                                                                                                                        [@B36]
                                     Binding to mutagenic compounds (HCAs)                                                                                                                                         [@B81]
                                     Removal of toxins and toxic metals                                                                                                                                            [@B112]; [@B209]
                                     Bacterial fermentation and production of SCFAs                                                                                                                                [@B20], [@B186], [@B237], [@B58]
  Additional health benefits         β-Galactosidase activity                                                                                                                                                      [@B124]
                                     Production of vitamins                                                                                                                                                        [@B222]
                                     Linolenic acid test                                                                                                                                                           [@B159]
                                     Oxalate-degradation                                                                                                                                                           [@B30]

According to current definitions, probiotics should be viable, even though sometimes dead microbial cells can also exert health benefits ([@B238]). It is also recommended that probiotics must be able to reach the desired body niches alive. An initial screening of strains based on various stress tolerance assays is of utmost importance ([@B275]), especially for non-encapsulated strains directly used in food. Hence, appropriate *in vitro* tests have been adopted to select strains based on their ability to survive transit through the different compartments of the gastrointestinal tract (GIT; [@B135]).

Survival of potential probiotic bacteria under simulated GIT conditions has been extensively studied over the last decades and strain-specific differences are marked throughout the literature. Following ingestion, probiotics first encounter the harsh conditions of the stomach and they must be able to survive under the extreme acidic conditions and the activities of the digestive enzymes. The pH of the stomach is known to fluctuate from 1--2 up to 4--5 after food consumption but most *in vitro* assays have been developed to select strains that withstand extreme low pH values. Most conventional methodologies include experiments studying the survival of strains in buffers with no nutrients like PBS or modified growth media, all adjusted to low pH. Similar experiments have not been reported for high values of pH, mimicking the slightly alkaline conditions of the small intestine, perhaps reflecting the notion that most probiotic strains are resistant to alkaline conditions. Acid tolerance tests are among the simplest tests that can be performed, allowing the routine screening of large numbers of strains. However, given the unrealistic harsh pH conditions employed during these tests, they may result in the loss of relatively acid sensitive probiotic candidates. For example, acid sensitive strains could be protected from the acid challenge of the stomach due to the buffering properties of food vehicles or specific food ingredients. Furthermore, the strains are most often challenged as pure cultures in either log or stationary phase, while in reality, probiotics are delivered to the host already stressed due to extended fermentation periods, food processing conditions, and storage. This pre-stressed state of probiotics may lead either to enhanced or diminished stress resistance during passage through the host, a property that may be species or even strain dependent.

Except for these simplified survival tests, artificial gastric as well as pancreatic juices have been developed to better represent the *in vivo* conditions ([@B40]). The survival in true gastric juice obtained from human individuals has been reported ([@B54]). Generally, synthetic gastric and pancreatic juices include the enzymes pepsin and pancreatin, respectively, and controlled incubation of strains in these juices have been investigated to mimic the time spent by probiotics in the upper and the lower GIT ([@B165]). Bile secreted in the small intestine reduces the survival of bacteria by disrupting the cell membrane, by inducing protein misfolding and denaturation and by damaging DNA. Bile salt hydrolase (BSH) is an enzyme that hydrolyses the amino acids of conjugated bile salts (glycine or taurine), reducing their toxicity. Tolerance to bile salt concentrations between 0.15 and 0.5% has been recommended for probiotics, which is in the range of the physiological concentrations met in the GIT ([@B106]). Again, bile tolerance assays may be easy to perform, but they may not particularly facilitate the reliable selection of probiotics, for several reasons. For example, in most cases strains are separately studied for acid or bile tolerance, despite the fact that these two stresses are actually sequential during passage through the GIT, increasing the stress pressure. The use of non-human bile may also raise some questions, as bovine or porcine bile do not have the same impact on microorganisms as human bile ([@B17]).

The need for more elaborate *in vitro* assays for testing the fate of probiotic strains in the GIT led to the development of several GIT simulators. More precisely, a multi-compartmental dynamic computer-controlled model simulating the stomach and the small intestine ([@B197]) has been used to quantify the survival of lactic acid bacteria (LAB) and the data obtained correlated well with those obtained from human subjects ([@B187]). In other cases, *in vitro* systems reproduce not only the conditions of the stomach and the small intestine but also those occurring in the oral cavity using an oro-gastric-intestinal (OGI) system ([@B24]). The simulator of the human intestinal microbial ecosystem (SHIME) was developed by inoculating human fecal material in a fermenter-based simulator to establish a GIT-like microbial population ([@B200]). Experiments with SHIME revealed similar survival rates of microorganisms to those obtained with *in vivo* tests ([@B55]). A modification of the SHIME system involved the incorporation of a mucosal environment in the SHIME model, resulting in a more representative colonization ability for the test strains ([@B278]). Another system that relied on two separate fermenters was designed to better simulate the physiological events of ingestion and digestion in the upper GIT. Using this system, it was possible to investigate the survival of probiotics through more realistic pH values, i.e., those that prevail prior, during and after a meal ([@B183]). Obviously, GIT simulators offer many advantages over independent *in vitro* tests and the selection of probiotic strains using these systems may be more reliable. However, such simulators do not allow rapid screening of multiple strains and they may be relatively expensive to maintain and operate. Today advancements in encapsulation technology allow the targeted delivery of probiotic strains to different compartments of the GIT in an active state irrespectively of their stress robustness.

SAFETY ASSAYS
-------------

Another important aspect in selecting probiotic strains is their safety status. While in Europe QPS regulation has identified the microorganisms that can be safely used in foods, there might be some safety aspects that may need to be evaluated before commercial probiotic cultures are put on the market ([@B135]). Laboratory tests applied for the safety evaluation of probiotic cultures include *in vitro* assays examining different intrinsic properties of the strains. Initially, the minimum inhibitory concentrations (MICs) for the most relevant antibiotics is usually determined and evaluated using protocols given by [@B73]. The microdilution-broth test performed on 96-well microplates ([@B7]), the disk-diffusing method ([@B220]) and ready-to-use commercial kits ([@B64]) have been applied to specify MIC values of known antibiotics for potential probiotic strains in many cases. Hemolytic activity is also examined ([@B135]). Clear zones of hydrolysis, partial hydrolysis or no reaction around the streaking of strains on blood agar plates indicate the hemolytic ability of probiotics ([@B220]). *In vitro* tests of pathogenic traits concern the ability of bacteria to bind to mammalian cells such as platelets, which is coupled with their binding to fibronectin, fibrinogen and collagen ([@B116]). The production of certain enzymes (e.g., glycosidases, proteases and gelatinases) is also perceived as a potential pathogenicity trait ([@B210]; [@B18]). Strains should be tested with appropriate *in vitro* assays for the production of known human toxins (e.g., cytolysins; [@B263]). Biogenic amines are usually generated by decarboxylation of the corresponding amino acids through substrate-specific decarboxylases of bacteria. Assays performed on solid media are based on the pH change of the medium after bacterial growth, corresponding to positive decarboxylase activity ([@B25]). Quantitative analysis of biogenic amines is generally accomplished by chromatography using amino acid analyzers ([@B111]). *In vitro* safety tests are generally very useful to identify and exclude clean-cut cases of pathogenic strains from being used as probiotics. For example, a hemolytic or a toxin producing strain can be easily identified and excluded from further analysis. The problem with the *in vitro* safety assays concerns the identification of false negative strains. A virulence trait may be simply non-active under the specific conditions of the assay and thus remain undetectable (e.g., a toxin that may be down-regulated *in vitro*). Virulence is a complex phenomenon that sometimes needs an active interaction with the host to be triggered and for this reason *in vivo* models may be more appropriate. The screening of the bacterial genome for the presence of virulence and resistance genes (see below) is also a way to predict the possibility of non-expressed safety risk factors.

COLONIZATION OF THE HOST AS A PREREQUISITE TO EXERT CERTAIN HEALTH BENEFITS
---------------------------------------------------------------------------

Although research in the probiotic area has considerably progressed the last decades, the correlation of specific cultures with specific health claims is still ambiguous. In a relatively limited number of cases specific *in vitro* assays have been devised to investigate the protective or therapeutic role of probiotic candidates against certain diseases. The simplest application is the competition of the probiotics with potential pathogens for resources and space in the GIT. Adherence to mucus and epithelial cells is still considered a controversial topic in probiotics research. On the one hand it is a desirable probiotic trait, as it facilitates colonization of the host and antagonism against pathogens, but on the other hand it is considered as a risk for translocation. The latter might be especially important in highly sensitive populations of immune depressed patients where probiotic applications are often considered ([@B243]).

The hydrophobicity phenotype of bacterial cell surface is related to their adhesive capacity and colonization of the gut ([@B214]). Generally, cell surface hydrophobicity is determined according to the capacity of the bacteria to partition into hydrocarbons (i.e., hexadecane, xylene, toluene; [@B142]; [@B132]), thus, reflecting the non-specific adhesion capability related to cell surface characteristics ([@B98]). Controversial results of hydrophobicity studies show that this feature might be questionable ([@B287]). In general, assessing the adhesive capacity of probiotic strains based on surface hydrophobicity is rather outdated.

Adhesion tests of probiotics to human intestinal mucus obtained from infants or healthy human feces have been performed ([@B151]; [@B84]). Moreover, high-throughput screening methods based on immobilized commercially available mucin have also been reported ([@B164]). Mucins are large glycoproteins that fortify intestinal mucosal surfaces forming a protective shield for the epithelial cells against harmful environmental conditions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expressed on the bacterial cell surface aid binding to human colonic mucin and the evaluation of this enzymatic activity has been reported as a simple screening method ([@B150]). Alternatively, other studies have focused on the ability of probiotic bacteria to form cellular aggregates via self-aggregation (auto-aggregation; [@B65]) by measuring absorbance of bacterial suspensions that are left standing for certain time intervals ([@B48]). Auto-aggregation capacity of LAB is correlated to their adhesion to different kind of host cells ([@B184]), and it is considered as a desirable characteristic for preliminary probiotic screening ([@B12]; [@B23]). Intestinal epithelial cell (IEC) lines are often presumed to better represent conditions in the tissues of the GIT (i.e., adhesion ability and colonization of probiotic strains). Several studies have been conducted using human epithelial cell lines (like HT-29, HT-29MTX, and Caco-2) to screen the adhesion of probiotic strains ([@B205]). In general, the *in vitro* testing of the adhesion potential is considered experimentally difficult. Reproducibility issues have been observed among laboratories due to the use of different variants of a given cell line and of high background levels ([@B151]). These tests can only yield rough indications of a strain's potential to adhere *in vivo*. Additionally, resected intestinal tissue fragments have been used unprocessed or immobilized on microtitre plates for adhesion assays ([@B284]). Finally, the whole tissue models consisting of the epithelial tissue with the mucus layer in the presence of commensal microbiota may allow the assessment of more complex adhesive interactions between probiotics and the host ([@B264]).

Several molecules that are actively aiding the binding to host's cells have been identified. The problem with the *in vitro* assays is their inability to recapture the actual conditions prevailing in the GIT. In most cases adhesion is studied for single strains thus in the absence of any additional microbiota that would mimic the gut microbiome. This is a very important drawback for most assays, since there is fierce competition for adhesion sites among the different microbes *in vivo*. The use of cancer cells is also a bit controversial since their extracellular matrix and surface properties may differ significantly from that of healthy IECs. Nevertheless, strains shown to adhere with high efficiency to human cells *in vitro* usually behaves in a similar manner *in vivo*.

ANTIMICROBIAL ASSAYS
--------------------

Another desired attribute is the production of antimicrobial compounds by probiotics. Perturbation of the GIT microbiome plays an important role in the pathophysiology of common gastrointestinal infectious diseases. Researchers have proposed that probiotics may prevent gastrointestinal disorders by maintaining homeostasis of the gut microbiome or by competitively inhibiting the growth of pathogens ([@B121]). Selection of probiotic bacteria active against infectious diarrhea attributed to viruses (e.g., rotavirus and norovirus; [@B3]) or bacteria (e.g., *Escherichia coli, Salmonella* and *Campylobacter* sp.) or to *Clostridium difficile* infection ([@B218]), is usually based on antimicrobial properties of probiotic strains. This is also the case for antibiotic-associated diarrhea ([@B59]) and *Helicobacter pylori* infection ([@B44]), as well as for infections related to sites of the human body other than the GIT, such as the oral cavity ([@B117]), the upper respiratory tract ([@B143]), and the urogenital system ([@B258]). In addition to the production of known antimicrobial metabolites such as organic acids, probiotic bacteria may also produce specialized inhibitory agents, like bacteriocins. Target strains commonly include both Gram positive and Gram negative bacteria, as well as fungal strains, comprising of not only pathogenic bacteria but also strains representative of the predominant human GIT microbiota ([@B96]). In general, antagonistic activity is evaluated *in vitro* using simple inhibition tests performed on solid media. More precisely, the agar spot test ([@B131]), the paper-disk diffusion assay ([@B110]), and the well diffusion assay ([@B262]) have been extensively used as methods for evaluating antimicrobial activity. Moreover, inhibitory effects of probiotic culture filtrates assessed by an automated turbidometric assay that monitors the ability of the indicator bacteria to grow has also been reported ([@B163]). In some cases, bioluminescent indicator strains were also used to investigate the possible production of antimicrobial compounds from probiotic bacteria ([@B162]). Assays as the cross-streak and the radial streak methods are comparatively more efficient in terms of examining the inhibitory properties of intact probiotic cells and not only properties attributed to their producing metabolites ([@B51]).

Antimicrobial ability of probiotics refers not only to the production of antimicrobial compounds or acids that affect luminal pH ([@B260]), but also the competitive exclusion of pathogens. Probiotics may compete with pathogens for binding sites on the surface of the GIT. The *in vitro* adhesion assays mentioned earlier can be used to assess the binding competition between probiotic and pathogenic strains. In this context, bacterial aggregation between genetically distinct cells (co-aggregation) is of considerable importance. Thus, protective properties of probiotics against pathogen infections can also be evaluated through co-aggregation assays based not only on simple absorbance measurements but also on radiolabelling and fluorescence detection ([@B49]).

Antimicrobial properties of probiotics are also correlated with the enhancement of the intestinal barrier function ([@B195]). Barrier properties can be investigated by measuring trans-epithelial electrical resistance (TEER) before and after apical exposure of IEC lines to bacteria ([@B304]). Promotion of tight junction integrity is known to block paracellular transport of pathogenic bacteria. Alterations of tight junction proteins are examined *in vitro* either by immunofluorescence using specific antibodies ([@B77]), or by evaluating the capacity of probiotics to alter tight junctional protein phosphorylation ([@B228]).

Once more, the *in vitro* production of antimicrobial substances alone cannot provide us with important information about the probiotics application *in vivo*. We cannot know if the selected strain will be able to be incorporated in the microbiome and whether the conditions prevailing in the GIT will allow it to produce its antimicrobial(s) compounds at sufficient amounts to have an effect. Usually, probiotic strains produce more than one antimicrobial substance that may act synergistically, increasing the spectrum of targeted microorganisms. This property may be desirable as long as this antimicrobial spectrum is restricted to pathogenic microorganisms but it cannot be excluded that it will not affect the normal microbiota of the gut as well. Similarly to other tests, antimicrobial assays may lead to false negatives, i.e., strains that are capable of biosynthesizing antimicrobial(s) but they do not produce it under the *in vitro* conditions employed. In addition, antimicrobials of probiotics are generally perceived as safe and in most cases the toxicity to host's cells is rarely investigated. There is a clear need for more elaborate assays that would better represent the complex interactions between the probiotics and the host microbiome to understand the consequences of the *in situ* production of antimicrobials by the former.

IMMUNOMODULATION
----------------

Modulation of host immunity is one of the most commonly proposed health benefits attributed to the consumption of probiotics. Probiotic selection that is correlated to the protection against microbial pathogens has been associated with the stimulation of antibody secretion, as well as cell-mediated immune responses ([@B60]). Evaluation of the bacterial translocation in the GIT can be used to screen potential probiotic strains, considering that some strains may be capable of triggering dendritic cells (DCs) or M cells from the Peyer's patches and thereby manage to cross the epithelium ([@B57]). In most of the *in vitro* experiments, researchers have attempted to reconcile the mechanisms underlying the complex and dynamic immune interactions of the gut by using co-culture models ([@B37]) or 3D models ([@B21]). The use of three component models (epithelia, immune cells and microbiota) closely mimics the *in vivo* situation ([@B90]). In addition, several reports highlight the complex interaction between the host immune system and different bacterial compounds, including chromosomal DNA, cell wall components such as lipoteichoic acids and peptidoglycan, as well as soluble metabolites ([@B57]). In these assays, cytokines like IL-5, IL-10, IL-12b, IL-17a, IFN-γ, TNF-α, and TGF-β, as well as the levels of the secretory immunoglobulin type A (sIgA) are used to assess stimulation of the immune response and the inflammation status ([@B196]; [@B257]).

IBD covers a family of chronic diseases affecting the GIT, having as most common forms Crohn's disease (CD) and ulcerative colitis (UC). Propitious functions of the probiotics for alleviation of IBD symptoms involve the ability to restore biodiversity within the microbiota, the antagonism against pathogens, the improvement of mucus production, the stimulation of epithelial proliferation, the modulation of intestinal permeability and the mediation of pro-inflammatory effects ([@B245]). *In vitro* models for probiotic selection in IBD research are alike to those mentioned previously. Specifically, assays that investigate the antimicrobial activity against microbes that help alter microbial biodiversity within the gut, the regulation of epithelial tight junctions and the induction of an anti-inflammatory cytokine profile (high IL-10/IL-12 ratio) from immune cells, are commonly used ([@B193]; [@B89]).

Allergy is a complex immune response to environmental or food antigenic stimuli and it is mostly correlated with the hypersensitivity reaction mediated by the interaction of immune cells coated with allergen-specific IgE that requires the involvement of T-cells with a Th2-skewed cytokine profile ([@B95]). Th2-skewed immune cells have extensively been studied to select probiotic strains that exert certain immune-stimulating properties for further *in vivo* use ([@B93]). Alleviation of allergic symptoms has also been correlated to the induction of the immunosuppressive cytokines IL-10 and TGF-β or the reduction of T-cell proliferation ([@B254]). The β-hexosaminidase release assay helps to identify potential anti-allergic probiotics, since the secretion of this molecule corresponds to a hallmark of allergic reactions resulting from exposure of mast cells to antigens ([@B148]).

Disturbance in the balance of the normal microbiome in different body niches can lead to inflammation. Probiotics known for their anti-inflammatory cytokine profile from immune cells can be efficacious in moderating this inflammation as in the case of caries and periodontal disease or of functional digestive disorders such as the irritable bowel syndrome (IBS; [@B158]; [@B103]).

While we found the measurement of cytokine levels produced by peripheral blood mononuclear cells (PBMCs) upon stimulation with probiotics to be a reliable and reproducible technique to identify strains with potential pro- or anti-inflammatory properties, the *in vivo* relevance can be questioned as the test involves only one type of immune cells and ignores the complexity of the *in vivo* communication between different cell types. The model is also blind for the differences between the innate and the adaptive immune system. Moreover, the model does not reflect differences of the immune system in relation to certain pathologies. Despite these limitations, experiments with PBMCs are of major interest, as they will allow to quantitatively classify strains and select strains with opposite profiles, e.g., for further mechanistic investigation.

CARDIOVASCULAR DISEASES (CVDs)
------------------------------

Several reports have demonstrated that manipulating the gut microbiome with probiotics may affect host metabolism and ultimately reduce the risk for CVDs. Increased bacterial BSH activity in probiotic strains can result in decreased body weight gain, lower levels of plasma cholesterol, and liver triglycerides ([@B35]). Bile salt hydrolyzing activity can be evaluated qualitatively by the plate assay method using taurodeoxycholic acid (TDCA) sodium salt ([@B61]), and quantitatively by high-performance liquid chromatography ([@B253]). The deconjugation of bile salts can lead to secretion of cholesterol and lipids via the fecal route ([@B302]). An *in vitro* assay for the conversion of cholesterol to coprostanol by the action of bacterial cholesterol reductase has also been described ([@B179]). In relation to cholesterol, coprostanol is less absorbed in the intestine and it can be easier removed with feces. Furthermore, the assimilation of cholesterol present in the growth media by probiotic strains has been tested *in vitro* ([@B265]).

Probiotic strains and metabolic by-products potentially confer benefits to the heart by the prevention and therapy of heart syndromes, as well as by lowering serum cholesterol ([@B71]). The ACE enzyme has a key role in the rennin--angiotensin system which controls the arterial blood pressure and the equilibrium of water and salt in the body. The hydrolysis of angiotensin I to angiotensin II, which is a strong vasoconstrictor agent from the ACE enzyme, can lead to an increase in blood pressure. During proteolysis of extracellular proteins like casein, peptides are being released that may inhibit ACE-I activity which is used as a screening tool ([@B216]).

There are several lines of evidence that support the positive implication of probiotics to the prevention of cardiovascular diseases ([@B71]). However, the actual mechanisms involved are not well understood and thus the *in vitro* assays available for this type of health claims are relatively restricted. Improving the barrier is generally considered an effective way to decrease basic physiological inflammation of e.g., adipose tissue, contributing to a reduced risk for the development of overweight and metabolic syndrome and therefore positively affecting CVD risks. A general comment can be made regarding the currently available assays for cholesterol absorption or its conversion to coprostanol. The length of these *in vitro* test protocols (often more than 20 h) may not match the *in vivo* time window for the absorption of cholesterol in the intestine after emulsification.

ANTICANCER
----------

The gut microbiota is considered to be related to the risk of cancer and it has been suggested that consumption of probiotics may decrease this risk. The important role of probiotics in retarding carcinogenesis is attributed to their ability to influence metabolic, immunologic, and protective functions in the body ([@B294]). Antimutagenic activities of probiotics have been evaluated by the Ames test ([@B29]). Probiotics also exerted an antigenotoxic activity related to decreased DNA damage of colon cells treated with carcinogens as evaluated by the "comet assay" ([@B223]). The nitrosamine degrading assay ([@B68]) and the evaluation of the antioxidant properties of bacterial samples, i.e., intact cells and cell-free culture supernatants, are used for the detection of potential probiotics against cancer ([@B4]). Bacterial cell-free culture supernatants of probiotic strains have also been tested for preventing colon cancer cell invasion *in vitro* ([@B45]). Strains showing *in vitro* inhibitory activity on tumor cell proliferation, induction of apoptotic cell death, and ability of cellular sphingolipidic metabolism, have been recognized as promising candidates for cancer prevention ([@B36]). Moreover, a possible mechanism of anti-carcinogenic properties of probiotic strains involves the physical binding by the bacterial cell of the mutagenic compounds, such as heterocyclic amines (HCAs). Specifically, bacterial strains that are able to sequester HCAs could decrease their absorption by the human intestine via their elimination through feces carryover ([@B81]). Furthermore, *in vitro* removal of toxins and toxic metals present in aqueous solutions or in drinking water has been studied for selected probiotics ([@B112]; [@B209]). Also, luminal short chain fatty acids (SCFAs), produced in the colonic lumen during bacterial fermentation, are known anti-carcinogenic agents within the gut ([@B52]). In the past, the influence of probiotic bacteria on the production of SCFAs by fecal bacteria was studied *in vitro* using batch-culture and continuous-culture techniques ([@B237]). *In vitro* GIT models as described above can also be used.

The aforementioned *in vitro* assays for anticancer properties of probiotic bacteria provide minimal information about the actual *in vivo* efficacy. On one hand, probiotic bacteria showing antimutagenic and/or antigenotoxic activities may exert generalized prophylaxis against gut related cancers. On the other hand, probiotics producing SCFAs may have a more direct effect by selectively killing cancer cells as it has been demonstrated for propionic acid bacteria ([@B58]) or by assisting in the renewal of the colonic epithelia by butyric acid ([@B186]) or its effect on histone deacytelase ([@B20]).

Generally, the existing *in vitro* assays are not sufficient to truly screen probiotics for anticancer properties and thus *in vivo* assays will be necessary. In any case, the idea of using bacteria (some of which are known probiotics, like bifidobacteria) in the treatment of cancer is gaining momentum ([@B46]). As the mechanisms of cancer prevention and therapy become clearer, new and more elaborate *in vitro* assays may be developed in the future.

ADDITIONAL HEALTH BENEFITS
--------------------------

There are several additional health benefits that have been attributed to probiotics. Lactose intolerance, attributed to an insufficient amount of lactase in the small intestine to early hydrolyze lactose, is an important problem when consuming milk or lactose containing foods ([@B146]; [@B38]). Dairy products containing probiotic bacteria could aid the digestion of lactose by their β-galactosidase enzyme when crossing or colonizing the gut. Screening for β-galactosidase activity in potential probiotics is assessed through the hydrolysis of the *o*-nitrophenol-β-galactopyranoside ([@B124]).

Other nutritional effects of probiotics relate to the production of vitamins. They play a major role in helping humans to meet their needs for these essential nutrients ([@B72]). *In vitro* studies have documented the capacity of some probiotic strains to synthesize vitamin K, folic acid, vitamin B2, and B12 ([@B222]).

Probiotics may also have a protective role against oxidative stress in the host ([@B256]). Oxidative stress has many physiological consequences to the host including aging, carcinogenesis, etc. Evaluation of the antioxidative activity of probiotics is usually assessed by the linolenic acid test (LA-test; [@B159]).

Furthermore, the role of oxalate-degrading bacteria in the treatment of kidney stone disease is of particular interest ([@B1]). Identification of potential probiotic strains through the evaluation of oxalate degradation by pure cultures has been reported ([@B30]).

Lastly, volatile sulfur compounds (VSCs) produced by oral bacteria can cause halitosis. An *in vitro* test was developed by [@B137] in which the influence of LAB on VSC production by *Fusobacterium nucleatum* could be assessed. Interestingly, inhibition of VSC production was related to co-aggregation of the LAB strains with *F. nucleatum* as well as the production of H~2~O~2~ by the former.

FUTURE PERSPECTIVES FOR THE USE OF *IN VITRO* TESTS IN PROBIOTIC RESEARCH
-------------------------------------------------------------------------

There are several *in vitro* assays that are being employed in an attempt to predetermine or document probiotic properties in relation to health claims. Even though such assays are useful to screen probiotic candidates they exhibit variable effectiveness. Regulatory authorities have attempted the standardization of the *in vitro* assays by publishing detailed protocols and directives. Unfortunately, even a superficial examination of the literature reveals that *in vitro* tests are being performed in a rather arbitrary manner. This makes it difficult to compare findings between different studies. Reproducibility issues have also been reported, making it difficult to rely solely on the outcomes of *in vitro* tests for the selection of probiotic strains. Apparently, *in vivo* assays may be more appropriate but in most cases they cannot be used for high throughput screening due to the increased cost and for ethical reasons. Therefore, *in vitro* screening is and will be an indispensable part of the discovery of new probiotics. More research is needed to improve and standardize the available experimental protocols aiming at improving reproducibility and decreasing the percentages of false positively or negatively identified strains with probiotic potential. Additionally, novel methods might need to be developed that will extend the health-promoting properties currently assessed with *in vitro* tests.

DISCOVERING PROBIOTIC MICROORGANISMS: *IN VIVO* APPROACHES
==========================================================

THE RIGHT MODEL FOR THE RIGHT PURPOSE
-------------------------------------

The use of *in vivo* approaches to explore probiotic potential resulted in the description of a huge diversity of biological models of various complexity, ranging from simple multicellular organisms such as worms and invertebrates over sophisticated knock-out (KO) models in rodents to human clinical trials in different types of the population (**Figure [1](#F1){ref-type="fig"}**; **Table [2](#T2){ref-type="table"}**). While all these models can teach us something, they also represent certain disadvantages and integrating results from different models remains difficult. Therefore, while final assessment of probiotic functionality should ideally be performed directly in the target population (general population or a subgroup with a given condition; [@B231]), the pre-selection of strains to be included in these expensive clinical trials might need to be made using appropriate *in vivo* models.

![**Progressive complexity of *in vivo* models used to support probiotic health effects**.](fmicb-06-00058-g001){#F1}

###### 

Advantages of using small animals/rodent models for probiotic research support.

  Functionality                                                                                                        Possible intervention/improvement                 Representative references
  -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------
  Physiological relevance for humans (Immune system, neuroendocrinological system)                                     Transgenic mice (knock-out/ knock-in)             [@B119]
  Closely related innate and adaptive immunity (PRRs and signaling cascades, secretory Ig, T and B cells, DCs, etc.)   Tissue-specific knock-out                         [@B255]
  Sharing of similar immune response types (Th1, Th2, Th17, Treg cells and cytokine responses)                         Conditional knock-out                             [@B255]
  Hosting complex microbiota (gut, vagina, lung, skin)                                                                 Humanized mice                                    [@B188]
                                                                                                                       Axenic mice                                       [@B283]
                                                                                                                       Monocolonized mice                                [@B70]
                                                                                                                       Microbiota transplantation                        [@B175]
                                                                                                                       Co-housing                                        [@B120]
                                                                                                                       Selective antibiotic treatment                    [@B126], [@B285]
  Responsiveness to many infectious, immune and other disorders                                                        Allergy, inflammation (asthma, COPD, IBD, etc.)   [@B145]
                                                                                                                       Bacteria, virus, fungi and parasites pathogens    [@B2], [@B286], [@B50], [@B144]
                                                                                                                       Neurologic disorders (EAE, visceral pain)         [@B74], [@B232], [@B161]
                                                                                                                       Stress, cognitive functions                       [@B102], [@B123]

Indeed, while rudimentary models such as *Caenorhabditis elegans*, or *Drosophila* exhibit obvious benefits for (large) screening purposes, they are also not devoid of relevance in deciphering more universal signaling pathways, even related to mammalian innate immunity, as shown by the work of the Nobel prize winner Hoffmann and his team ([@B288]). *C. elegans* was successfully applied to establish the anti-infective, antioxidative and lifespan extending impact of lactobacilli ([@B289]; [@B107]). The prototype worm is currently proposed to screen probiotics ([@B217]), or to establish antitumor activity ([@B82]). In a similar way, the fly is useful to explore metabolic, immune and antioxidant effects of the *Lactobacillus*-host mutualism ([@B136]; [@B189]).

Quite recently, the zebrafish (*Danio rerio*) has garnered intense interest as a human disease model ([@B178]) due to its many advantages as an experimental vertebrate. It now appears that the zebrafish can be used for high-throughput screening (e.g., of drug libraries) in the discovery process of promising new therapeutics ([@B176]). The latter was successfully developed for probiotics, showing that probiotic administration may enhance the zebrafish welfare by modulating the innate immune response and improving hepatic stress tolerance, involving stress and apoptosis genes, and genes from the innate immune system ([@B104]; [@B230]). Of note, zebrafish can also partly mimic characteristics of IBDs when larvae are subjected to chemicals such as trinitrobenzene sulfonic acid (TNBS; [@B86]) or when encountering unfavorable conditions, including dysbiosis of the intestinal microbiota ([@B118]). Modifications include colitis susceptibility genes like *NOD1* and *NOD2* ([@B211]), enabling the routine evaluation of anti-inflammatory compounds.

RODENTS AS THE NECESSARY COMPROMISE
-----------------------------------

The small animal models mentioned above clearly meet the needs for cost effective and public-acceptable screening but are still far away from an integrated mammalian physiology. Therefore more pertinent experimental models are required for the evaluation of probiotic functionality, allowing to study various dynamic states and when addressing specific diseases with multifactorial origins.

Accuracy of the results of animal models is not always in perfect accordance with human outcomes and may sometimes appear problematic as it was for example recently stated: "Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice" ([@B172]; [@B249]). Whether animals can be used to predict human response to drugs, chemicals or foods (including probiotics) is apparently a contentious issue. While some will promote a ban on animal experimentation which lacks scientific evidence for human predictivity ([@B153]), the relevance of e.g., mice disease models for humans has been judged rather positively during a dedicated European Commission workshop held in the UK^[1](#fn01){ref-type="fn"}^. However, a certain level of criticism on the relevance of animal models does apply. [@B250] illustrate with numerous examples their importance, or lack thereof, in the different steps of the complete research process. They discuss, as an example, the bioavailability differences between primates, rodents, and dogs. When specifically considering probiotic interactions with the host microbiota, a deeper comprehension of the symbiosis between animals and bacteria is key to understanding the complex biology of environmental, genetic and microbiome interactions in relation to human health and disease evolution. [@B157] reviewed how model systems are influencing the current understanding of host--microbiota interactions by exploring recent human microbiome studies. They conclude that experimental model systems, including mice, fish, insects, and the Hawaiian bobtail squid, continue to provide critical insight into how host--microbiota homeostasis is constructed and maintained. Taking also into account the dynamics of the human microbiome through human life stages, predictive value of simple models may indeed have its limits, but their use may be crucial in understanding mechanisms of interactions and regulation of metabolic, physiological, and immunological activities.

Effective use of rodent models will depend on extreme standardization, including the microbiota composition. Relevance for the human situation needs to be considered at any time, as e.g., many bacterial species which are commensal for humans can be pathogenic in mice and *vice versa* ([@B11]; [@B215]). Despite all these possible drawbacks, small animals such as rats and mice will inevitably be continued to be used as models to address numerous research questions related to probiotics, including the evaluation of immune and metabolic responsiveness, regulatory processes or neuro-endocrinological and nutritional aspects, which all play important roles in the complex microbiota--host relationships. Moreover, small animals permit to mimic specific diseases, e.g., by using genetically modified specimens (conditional and tissues-specific knock-in/knock-out mutants, **Table [2](#T2){ref-type="table"}**) or specific chemicals (e.g., TNBS to induce intestinal inflammation) and infectious challenges, while manipulation of the microbiota allows to question the role of (a) specific microorganism(s) (**Table [2](#T2){ref-type="table"}**).

FITTING ETHICS AND LEGISLATION
------------------------------

Controversy on animal experimentation has always been high. Researchers in need of animal models have to cope with ethical and legal considerations, as well as with a public opinion that often is not fully aware of the economic and societal importance of the research envisaged, nor of the regulatory context which also limits the unethical use of animal suffering. Researchers are also actively required to ensure that animal models (i) are scientifically (and statistically) validated (ii) cannot be replaced by *in vitro* alternatives and (iii) minimize animal suffering by limiting the number of animals and the length of the experimentation to what is statistically required. Research strategies and methods should be challenged continuously and reviewed objectively with respect to the 3Rs rule established more than 50 years ago, i.e., use opportunities to replace, reduce and refine ([@B235]). In addition to the proper management of pain by analgesia and anesthesia, welfare accommodations improved tremendously following the most recent US and EU animal housing guidelines. Mice and rats should be allowed sufficient space of adequate complexity, allowing to express a wide range of normal behaviors, and providing enrichment possibilities to promote physical exercise, foraging, manipulative and cognitive activities, whenever possible ([@B229]).

In this review we do not focus on the use of large mammals (pigs, dogs, or monkeys) as these are not widely available and ethical considerations are considerable. Non-invasive dietary interventions with pigs, however, may have an interest as the GIT of pigs resembles very well the human GIT.

MODELING DISEASES TO SUBSTANTIATE HEALTH EFFECTS
------------------------------------------------

Probiotic activity is situated on three main levels ([@B231]): (i) influence on the growth or survival of pathogenic microorganisms in the gut lumen (level 1), (ii) improvement of the mucosal barrier function and the mucosal immune system (level 2) and, (iii) beyond the gut, effects on the systemic immune system, remote organs and systems such as the liver and the brain (level 3). Correspondingly, *in vivo* approaches intended to substantiate probiotic effects might consider these three levels through gastrointestinal infection models, mucosal immune disorder models and models dealing with dedicated experimental neuro-metabolic pathologies respectively.

Maintaining or improving overall "health" is difficult to demonstrate in humans and *a fortiori* in animals. Health claim evidence for probiotics obviously starts by proving innocuousness of the probiotic strain and its matrix and by clearly establishing its safety, using adapted procedures ([@B280]; [@B243]). In a second step, the model must fit the purpose of showing convincingly the projected functionality of the probiotic strain, either in a prophylactic or therapeutic way, or demonstrating a reduction of risk activity. This functionality must be illustrated either using read-outs that are relevant for the human situation, in appropriate terms of expected changes in metabolism, physiology, immunology, etc. or by a measurable limitation of the severity or frequency of disease. Discriminating, relevant physio-pathological markers are crucial and should reflect the targeted probiotic functionality. Clearly, the anti-infectious impact of probiotics, depicted for example by the survival rate of a defined pathogen, can only be considered for that particular pathogen and should not be extended to other infections. Consequently, optimal read-outs have to be selected as clear markers of pathology. In the case of inflammation, various pathological as well as beneficial changes may take place. For instance, we routinely determine IL-10 production in inflamed tissues and observed increased amounts of this anti-inflammatory cytokine in the colon of mice following TNBS or dextran sodium sulfate (DSS) treatment, as compared to healthy mice. While IL-10 is a "regenerating" mediator, rapidly induced by injured tissues in response to damage ([@B13]), it is not an appropriate marker for efficacy in inflamed situations, where IL-10 is to be considered a marker of inflammation. However, in the context of a healthy mucosa, probiotics and other prophylactic anti-inflammatory drugs may be able to substantially increase baseline levels of IL-10 and TGF-α, and thus prevent further injuries.

INTESTINAL MODELS FOR INFLAMMATION AND INFECTION
------------------------------------------------

For the evaluation of the anti-inflammatory activity of bacteria, several colitis models can currently be used. In many cases the reduction of chemically induced inflammation, e.g., induced by TNBS or DSS, is measured (see [@B47] for a complete review). These models are mostly acute models, while chronic ones are less common. They obviously only mimic symptoms of IBD such as UC and CD but do not cause the real disease. Therefore, each model has its own specificity and some interventions may have opposite effects in different models. TNBS evokes an inflammatory process involving T cells while the acute DSS model is more likely to induce epithelial barrier disturbances ([@B87]).

The IL-10 KO mouse model may also be used to study probiotics, but the spontaneous colitis that progressively will occur is not homogenous, difficult to control in time and highly dependent on animal facility conditions. Sometimes additional treatments such as *Helicobacter* infections or small amounts of DSS are required to trigger the onset of inflammation. Clearly, the choice of a model will depend on the putative mode of action of the probiotic used. The IL-10 KO mouse model abolishes a key regulatory cytokine and may thus exclude a virtually protective probiotic if the main mechanism is IL-10 dependent. Similarly, while *nod1*/*nod2* KO mice are good models for CD, the fact that they lack the cellular receptor for peptidoglycan and derived anti-inflammatory products (i.e., certain muramidyl di- or tri-peptides), will at the same time exclude the efficient study of bacteria that execute their anti-inflammatory effect in this way ([@B180]). In general, KO mice models, especially those deficient for key receptors such as TLRs, are appropriate for case-by-case studies, often aiming at confirming specific mechanisms of action, but are less suitable for broader screening purposes.

Finally, some other models of colitis involve adoptive transfer of specific T cells (CD4^+^CD45rb) in immune-deficient animals (SCID, Rag^-/-^) allowing to explore the impact of probiotics on adaptive immunity. *Citrobacter rodentium* is a murine pathogen that induces, depending on the genetic background of the mice, variable degrees of infectious and inflammatory responses, ranging from infectious colitis to severe and fast lethal inflammation. It shares several pathogenic mechanisms with enteropathogenic *E. coli* (EPEC) and enterohaemorrhagic *E. coli* (EHEC), two clinically important human gastrointestinal pathogens, showing severe adhesion-based virulence in the intestinal mucosa. The models also display crypt hyperplasia, demonstrating similarities with pre-carcinogenic states. Some probiotics have been shown to positively alleviate *C. rodentium*-induced colitis as demonstrated for lactobacilli, bifidobacteria, propionibacteria, yeasts and spores of *Bacillus subtillis* ([@B41]; [@B134]; [@B296]; [@B88]; [@B50]). This model, when appropriately used, can be considered a model of choice to investigate overall probiotic functionality ([@B22]) as it reveals information on the anti-infectious as well as the anti-inflammatory potential of the strains tested.

*Clostridium difficile* can be the causative agent of primary and recurrent antibiotic-associated diarrhea and colitis in hospitalized patients. Mice models to mimic this type of infection exist but require the administration of a broad range of antibiotics that are not always compatible with the planned probiotic interventions ([@B43]; [@B261]). Therefore, the preferential use of yeasts such *Saccharomyces boulardii* has been suggested ([@B14]), or the window of intervention is to be kept quite short to demonstrate substantial effects ([@B141]). Partial efficacy has been shown on inflammation or stool consistency parameters, although the infection was not completely cured ([@B85]). Further efforts are needed to optimize the model for more detailed study of promising probiotic strains.

Similarly to *Clostridium difficile*, a *Salmonella typhimurium* infection in mice requires the administration of antibiotics during the colonization ([@B115]), limiting also the readouts of the model. However, infectious challenges with *S. enterica* can be useful to study mortality and translocation ([@B303]; [@B63]; [@B301]), focusing on indirect anti-inflammatory effects and on the impact of the probiotics on the intestinal barrier.

Finally, listeriosis is not spontaneously modeled in mice and infectivity would require genetically modified humanized animals having the necessary receptor to allow the pathogen to attach and disseminate within the host. When established, it might allow to explore anti-infective probiotic potentials against *Listeria* ([@B6]).

CANCER MODELS
-------------

While animal models exist for chemopreventive and chemotherapeutical drugs for e.g., mammary and ovary cancer, bladder, and prostate cancer, esophagus and colon cancer, lung and pancreas cancer, skin head and neck cancer, most studies involving probiotics focused on colorectal cancer (CRC), as it represents the most common malignancy of the GIT and has been linked to dietary habits and a Western lifestyle. Many indications have indeed pointed toward the importance of the microbiota in the increased risk for CRC development. Several possible mechanisms for reducing the risk for CRC development have been suggested, each supported by *in vitro* and *in vivo* models ([@B274]). Probiotic intervention intends to alter the metabolism of the microbiota by reducing intestinal enzymes that promote the production of potential carcinogenic substances: β-glucuronidase that produces aglycons, or nitroreductase and azoreductase, which produce free amines from aromatic nitroso compounds and azo dyes respectively ([@B105]).

A second mechanism includes the direct inactivation of potential carcinogenic compounds, such as mutagenic derivatives of heterocyclic aromatic amines. Commensal bacteria have been found to bind or metabolize these compounds, resulting in reduced mutagenicity in HCA exposure models ([@B160]), reduced bioavailability of other mutagens in the GIT and tissues in mice ([@B213]) or increased detoxification in rats ([@B39]). Another way to study probiotic efficiency in reducing the prevalence of CRC is the IL-10 KO mice model ([@B212]), leading to spontaneous colitis and colon cancer development.

Improving the host's immune response by activation of antigen-presenting cells, natural killer cells or subsets of T and B cells is another way to promote antitumor activity in mice ([@B247]) and may explain some of the observations in syngeneic mice and guinea pigs on Lewis lung carcinoma and line-10 hepatoma ([@B191]), as well as in bladder cancer in man ([@B9]). The same probiotic strain was also shown to have a positive effect on transplantable tumor cells and to suppress chemically-induced carcinogenesis in rodents ([@B192]). A component of the polysaccharide peptidoglycan complex was shown to improve colitis-associated cancer in mice ([@B190]). Measuring survival rates of mice injected with tumor cells is another model that can be used to test or compare the potential of different probiotic strains to increase cellular immunity ([@B171]).

Anti-proliferative effects by regulation of apoptosis and cell differentiation have been described in response to the carcinogen azoxymethane (AOM; [@B173]), which may be linked to reduced levels of ornithine decarboxylase involved in polyamine biosynthesis ([@B201]). Butyrate also enhances cellular differentiation and reduces proliferation ([@B266]). Butyrate may be used as an energy source by the colonocytes and together with other SCFAs they may reduce the colonic pH and the concentration of secondary bile salts. In addition, conjugated linoleic acids (CLAs) were also shown to have anti-inflammatory and anti-carcinogenic effects ([@B149]; [@B78]; [@B75]), possibly through the activation of PPARγ.

Besides for CRC, the Apc^Min^ mouse model can also be used in the case of mammary tumorigenesis ([@B202]). [@B42] used this model to examine the quantitative and mechanistic effects of probiotic yeast on the induction of intestinal tumors. Clearly a large number of models exist for the investigation of probiotic activities on cancer, reflecting the many possible mechanisms of probiotic activity, as well as the intense cancer research activity.

MODELS LOOKING INTO METABOLIC DISORDERS
---------------------------------------

Metabolic syndrome (MS) is a complex multifactorial disorder involving genetic predisposition, life style, diet, and environmental factors and is almost always accompanied by an increased risk of cardiovascular diseases and type 2 diabetes, and possibly also non-alcoholic fatty liver disease (NAFLD) and hypertension. Obesity is the most important precursor for MS, especially on a longer term. Pro- and prebiotics can play a role in weight management, as obesity was found to be linked to a dysbalance of the microbiota, both in mice and man ([@B177]). [@B267] investigated the inter-relationship between diet, microbial ecology of the gut and energy balance using a Western diet-induced obesity model in mice. This diet induced a dominance of the Firmicutes in the distal gut microbiota which could be reversed by subsequent dietary manipulations to limit weight gain. Interestingly the transplantation to germ-free lean mice of the microbiota from mice with diet-induced obesity, increased significantly more the adiposity in the recipient mice than transplants from lean donor mice. Possible mechanisms include a change in intestinal permeability, leading to decreased translocation of lipopolysaccharides in the microbiota of lean mice and therefore to decreased inflammation and abdominal adiposity ([@B32]). Also the importance of *A. muciniphila* in this process has recently been illustrated ([@B76]). Overall these observations have fuelled the idea of using probiotics and prebiotics in dietary strategies for weight management ([@B208]; [@B34]). Again, several mechanisms, and thus several models, can be considered to improve gut microbial balance: CLA production ([@B169]), polyphenol supplementation, low amounts of probiotics ([@B226]), prebiotic intake, decreased food intake, increased satiety, increased barrier function or ways to decreased abdominal adiposity or total cholesterol levels ([@B297]). Since it is impossible to describe all MS related animal models here, it is important to note that the cause/consequence relationship is not clear when only considering the composition change of the microbiota related to obesity, as many of the models involve high-fat diets, also directly affecting the microbial composition ([@B122]). The use of germ-free mice with standardized nutrition might help to study the direct impact of a particular microbiota composition on MS. The observed shifts in the microbiota composition may have an impact on the barrier function, but they have also been linked to functional shifts (e.g., production of SCFAs) in the microbiota which can contribute to an obese phenotype ([@B268]). Important to notice as well, is the observation that the situation in humans seems to be different from mice, since bacteroidetes-related taxa were either reported to increase, to remain unchanged, or to decrease after weight loss ([@B69]; [@B207]). The detection of the *ob* and *db* genes in mice led to the development of several animal models to study obesity effects ([@B127]; [@B125]; [@B53]). The *ob* gene, located on chromosome 6, encodes the hormone leptin and renders *ob/ob* mice massively obese, with marked hyperphagia and mild transient diabetes, while the *db* gene, located on chromosome 4, codes for the leptin receptor and renders the *db/db* mice markedly obese with hyperphagia, but with severe, life-shortening diabetes.

One can conclude that the complex interplay between genetics, environment, diet, the microbiota and its metabolism or the barrier and immune function of the host, make it difficult to develop all-round animal models. Partial mechanisms may need to be put forward for independent evaluation, with the total picture being obtained through the combination of different *in vitro* and *in vivo* models. Translation from animal to man may also prove to be difficult, because of this complexity.

MODELS FOR AUTO-IMMUNE DISEASES
-------------------------------

Similarly to MS, auto-immune disease (AID) covers a broad range of possible diseases (type 1 diabetes, multiple sclerosis, rheumatoid arthritis, pemphigus vulgaris, scleroderma, Sjögren's syndrome, etc.) involving, besides genetic factors, also an aberrant intestinal microbiota, a disturbed mucosal barrier and altered intestinal immune responsiveness. All these factors share functional links and will therefore determine the models to be considered for more in depth study of probiotic mechanisms or for comparing different strains. Since probiotics have the potential to interfere with all three factors, one will need to try and find strains that have the capacity to change in a positive direction any, or any combination, of these factors. As for the intestinal immune responsiveness, interest will be in anti-inflammatory probiotics, as chronic inflammation underlies many AIDs and is often at the start of its development, as in rheumatoid arthritis. It is also not clear if the AID is caused by inflammation, or the other way around.

Animal models such as the non-obese diabetic mice will spontaneously develop diabetes resembling human insulin-dependent diabetes mellitus ([@B100]; [@B139]). The fact that in these mice a progressive lymphocytic infiltration of autoreactive CD8^+^ T cells into the islets of Langerhans will cause insulitis positioned the model as a model of AID. In another model, considered a good model of rheumatoid arthritis in humans, a probiotic strain prevented the onset of type II collagen-induced arthritis in DBA/1 mice ([@B140]). Results suggest that the probiotic was able to modify the systemic humoral and cellular immunity and could elicit alterations of the immune state in this model. In general there are many conflicting data on the effect of probiotics in AID. In part this uncertainty comes from the diversity of the strains evaluated, while the different genetic backgrounds of the host might also be an important reason.

FUTURE PERSPECTIVES FOR THE USE OF *IN VIVO* TESTS IN PROBIOTIC RESEARCH
------------------------------------------------------------------------

To increase the accuracy of animal models, multi-humanized mice can be considered, carrying functional human genes, cells, tissues, or organs. Immune-deficient mice are often used as recipients for human cells or tissues, because they can relatively easily accept heterologous cells due to lack of host immunity. Traditionally, nude mice and severe combined immunodeficiency (SCID) mice have been used for this purpose, but many other models have been shown to engraft human cells and tissues even more efficiently ([@B128]). These humanized mouse models may assist to model the human immune system in various scenarios of health and disease, and may enable the evaluation of therapeutic candidates in an *in vivo* setting more close to human physiology. While those specific humanized mice are commonly used in biological and medical research for human therapeutics, they do not frequently appear in probiotic research yet.

Given the importance of the microbiota for many immune and metabolic functionalities of the host, the development and use of mice models with an artificially composed microbiota, e.g., a human microbiota, might help to better mimic the human condition. The use of axenic or monoxenic mice may help to unravel the "egg or the chicken" question mentioned above. The impact of a dietary intervention with or without a microbiota can learn interesting things about the direct influence of the administered probiotic versus e.g., an indirect metabolic or microbiological effect or can show the direct impact on the immune system of any planned intervention.

As for the ethical problem of using animal models, interesting developments such as seen at the Wageningen University in The Netherlands, may bring some solution in the future. *In silico* solutions may try to represent the interactions of the pig gut, the nutrients and other feed/food components with the residing microbes and with epithelial cells. All elements are considered as nodes in a mathematical model, together with their mutual, quantitative dependencies^[2](#fn02){ref-type="fn"}^. Using these model interactions, a number of higher level processes related to intestinal immunity, tolerance and barrier functions can possibly be simulated, and conditions as gut homeostasis could possibly be better understood. On a longer term, the model may even evolve into a dynamic and predictive one, allowing to test hypotheses.

DISCOVERING PROBIOTICS WITH GENETICS AND OMICS
==============================================

STRESS RESPONSES
----------------

Over the past two decades several attempts have been made to identify molecular markers that would facilitate the rapid selection of probiotic strains (**Table [3](#T3){ref-type="table"}**). To elucidate the complex adaptation mechanisms of probiotic microorganisms under stress conditions, several genetic and omics studies have been conducted in an attempt to identify gene expression and/or protein production patterns related to stress. The exposure of cells to gastric acidity causes reduction of intracellular pH, which adversely affects numerous cell wall and transmembrane-based processes and damages proteins, nucleic acids and other cellular macromolecules. To resist acid stress, microorganisms employ mechanisms aiming at the maintenance of the intracellular pH homeostasis, the repair of macromolecular structures like the cell envelope or ribosomes and other damaged molecules ([@B168]). Heat shock proteins are molecular chaperones involved in the repair of acid-damaged proteins. Many studies have demonstrated that several heat shock proteins, e.g., DnaK, GroES, GroEL, GrpE are induced by acid stress, but their induction varies among different species/strains ([@B114]). In parallel, the Clp proteases (e.g., ClpP, ClpE, ClpL) are also induced under acid stress targeting denatured proteins to re-fold them to the appropriate structure or to degrade them if they are beyond repair ([@B83]; [@B114]). Genes implicated in DNA repair were also found to be up-regulated under acidic stress (e.g., *uvrB*, *uvrD1, vsr;* [@B133]). Furthermore, an essential component in the response against low pH is the up-regulation of the F~1~F~0~-ATPase ([@B242]; [@B133]; [@B155]). The various subunits of this multimeric enzyme are being encoded by eight genes found on the *atp* acid inducible operon. The F~1~F~0~-ATPase lowers the cytoplasmic concentration of protons by virtually extruding them to the extracellular environment at the expense of ATP which can ultimately lead to energy depletion and growth arrest. The composition of the cell envelope is also altered upon exposure to acidic conditions to decrease its permeability to protons. Genes and proteins involved in peptidoglycan biosynthesis (e.g., *manB*, *glmU*, *dapA*, glycosyltransferases), in [D]{.smallcaps}-alanylation of lipoteichoic acids (e.g., *dlt* operon), in fatty acid (e.g., *fab* genes) and exopolysaccharide (EPS; e.g., Etk-like tyrosine kinase) biosynthesis were induced to ameliorate the cells' resistance to acid stress ([@B219]; [@B133]; [@B155]). In addition proteins involved in cell envelope biogenesis (e.g., FabF, RfbB, RfbC) were shown to have a strain-specific role in acid tolerance ([@B114]). The gene *luxS* exhibited enhanced expression under acidic conditions in several probiotics, implicating quorum sensing (QS) in acid stress resistance ([@B203]; [@B155]).

###### 

Potential gene/protein markers related to different probiotic properties identified during genetic and omics studies.

  Gene/protein                                                                                                                           Function                                                                                                                Representative references
  -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  **Stress responses (acid and bile)**                                                                                                                                                                                                                           
  Heat shock proteins (e.g., DnaK, GroES, GroEL, GrpE)                                                                                   Repair of damaged proteins                                                                                              [@B295], [@B234], [@B114]
  Clp proteases (e.g., ClpP, ClpE, ClpL)                                                                                                 Refolding or degrading denatured proteins                                                                               [@B83], [@B114]
  *uvrB*, *uvrD1, vsr*, helicases                                                                                                        DNA repair                                                                                                              [@B133], [@B5]
  F~1~F~0~-ATPase                                                                                                                        Decrease of intracellular pH                                                                                            [@B242], [@B113], [@B133], [@B155]
  *manB, glmU, dapA*, glycosyltransferases                                                                                               Peptidoglycan biosynthesis                                                                                              [@B133]
  *dlt* operon                                                                                                                           [D]{.smallcaps}-alanylation of lipoteichoic acids                                                                       [@B219], [@B156]
  *fab* genes                                                                                                                            Fatty acid biosynthesis                                                                                                 [@B155], [@B5]
  Etk-like tyrosine kinase, *welG*                                                                                                       Exopolysaccharide biosynthesis                                                                                          [@B156], [@B133]
  FabF, RfbB, RfbC                                                                                                                       Cell envelope biogenesis                                                                                                [@B114]
  *luxS*                                                                                                                                 Cell-to-cell communication                                                                                              [@B203], [@B295], [@B155]
  *bsh*                                                                                                                                  Deconjugation of bile salts                                                                                             [@B113], [@B156], [@B5]
  Transporters                                                                                                                           Bile eﬄux                                                                                                               [@B224], [@B109], [@B156], [@B234], [@B5]
  **Adhesion**                                                                                                                                                                                                                                                   
  Mub                                                                                                                                    Cell-surface proteins with cell wall anchoring motif (LPXTG)                                                            [@B10], [@B182], [@B292], [@B269]
  *slpA*                                                                                                                                 S-layer protein                                                                                                         [@B79], [@B8], [@B16], [@B269]
  Apf                                                                                                                                    Aggregation promoting factor                                                                                            [@B282], [@B269]
  *srtA*                                                                                                                                 Sortase-dependent surface protein                                                                                       [@B206]
  *spaCBA*, *spaFED*, *pil2*, *pil3, fim1, fim2, fim3*                                                                                   Sortase-dependent biosynthesis of pili                                                                                  [@B138], [@B91], [@B101], [@B293], [@B67], [@B273]
  FbpA, E1 β-subunit of the pyruvate dehydrogenase complex                                                                               Fibronectin binding protein                                                                                             [@B10], [@B292], [@B281]
  *tad*                                                                                                                                  Assembly of tide adherence pilus                                                                                        [@B293]
  **Degradation of HMOs and Mucus**                                                                                                                                                                                                                              
  43 kbp gene cluster                                                                                                                    Catabolism of HMOs                                                                                                      [@B248]
  F1SBPs                                                                                                                                 Import of oligosaccharides                                                                                              [@B248]
  β-Galactosidases                                                                                                                       Degradations of type-1 and type-2 HMOs                                                                                  [@B300]
  Glycosylases                                                                                                                           Degradation of HMOs                                                                                                     [@B147]
  Glycosyl hydrolases, exo-α-sialidases, fucosidases, PTS systems, ABC-type carriers, specific permeases, *engBF*, *afcA,* NagBb, AgnB   Mucin degradation                                                                                                       [@B299], [@B233], [@B270], [@B272]), [@B152], [@B251]
  *adh*                                                                                                                                  Adhesion and stimulation of mucin secretion                                                                             [@B181]
  Soluble protein p40                                                                                                                    Stimulation of mucin production                                                                                         [@B290]
  **Modulation of the immune system**                                                                                                                                                                                                                            
  p40 and p75 proteins and homologues                                                                                                    Activation Akt, promotion of cell growth, inhibition of TNF-α                                                           [@B298], [@B15]
  ClpB, Rpf                                                                                                                              Potential immunogenic proteins                                                                                          [@B101]
  SLPs (SlpA, InlA, LspA, SlpE, SlpB), additional disperse genetic loci                                                                  Regulation of anti- or pro-inflammatory immune responses (e.g., induction of the IL-10 and IL-6 regulatory cytokines)   [@B154], [@B194], [@B279], [@B16], [@B174]
  *ser*                                                                                                                                  Inhibition of elastases                                                                                                 [@B271]
  Cell surface-associated EPS                                                                                                            Adaptive immune response and protection against the gut pathogen *Citrobacter rodentium*                                [@B80]
  Flagellin                                                                                                                              Induction of human β-defensin 2 (hBD-2)                                                                                 [@B246]
  **Production of antimicrobial compounds**                                                                                                                                                                                                                      
  Bacteriocins                                                                                                                           Protection against enteropathogens                                                                                      [@B56]
  Genes involved in plantaricin biosynthesis and secretion                                                                               Regulation of pro- and anti-inflammatory cytokines of DCs                                                               [@B194]
  **Quorum sensing**                                                                                                                                                                                                                                             
  *luxS*                                                                                                                                 Induction of anti-inflammatory cytokines Adhesion and competitive exclusion of pathogens                                [@B130] [@B28], [@B204]
  *lamBDCA* operon, *lamKR* operon                                                                                                       *agr*-like quorum sensing systems                                                                                       [@B259], [@B92]
  Quorum sensing system related peptide (CHWPR)                                                                                          Induction of *c-myc* and *IL-6* genes in somatic cells                                                                  [@B199]
  **Production of nutrients and other beneficial processes**                                                                                                                                                                                                     
  Vitamins, essential amino acids, SCFAs                                                                                                 *In situ* production of important nutrients                                                                             [@B79], [@B244]
  *fos*                                                                                                                                  Processing of health-promoting fructooligosaccharides                                                                   [@B236], [@B147]
  ABC carbohydrate transporters                                                                                                          High production of acetate and protection from enteropathogenic infection                                               [@B94]
  *ccpA*                                                                                                                                 Influencing blood cholesterol                                                                                           [@B170]

As discussed above, having survived the hostile environment of the stomach, probiotics next have to face bile in the duodenum. Many transcriptomics and proteomics studies have been performed to determine bile resistance factors in probiotic strains. Interestingly, several of the pathways that are activated during acid stress in the stomach seem to be involved in the ability of probiotics to adapt to bile, as well. Responses against bile include the increased expression of molecular chaperones (e.g., GroEL, GroES, HSP20, DnaK), proteases (e.g., Clps, DegQ), DNA repair proteins (e.g., helicase) and of the F~1~F~0~-ATPase ([@B295]; [@B113]; [@B234]; [@B83]; [@B5]). Genes involved in EPS (e.g., *eps*, *welG*) or fatty acid biosynthesis (e.g., *acc*, *fab*) have been found down-regulated ([@B156]; [@B5]). In contrast the *dlt* operon was up-regulated ([@B156]). It is generally accepted that cells attempt to protect the integrity of the cell envelope by appropriately regulating cell wall and cell membrane processes ([@B168]). Apart from these generic mechanisms that may also be induced by other stresses, there are some that are obviously specific for bile stress. The BSHs encoding genes were found to be up-regulated under bile stress in many studies ([@B113]; [@B156]; [@B5]). However, this is not always the case indicating differences in the regulation of BSH among probiotic strains ([@B240]). Bile export from the cell is another mechanism to counterbalance bile toxicity. Permeases of the major facilitator superfamily (MFS) have been found to be up-regulated and could play a similar role with the bile-inducible eﬄux transporter BetA. Also ABC (ATP-binding cassette) transporters could play a role in bile expulsion ([@B156]; [@B234]; [@B5]). Probiotic microorganisms also use multidrug resistance (MDR) bile eﬄux transporters to actively pump bile salts out of the cytoplasm. Several MDR genes (e.g., *betA*, *ctr*) have been reported to be induced under bile stress ([@B224]; [@B109]).

The molecular basis of the stress physiology of LAB and other probiotics has advanced rapidly over the past years ([@B26]; [@B275]). As our understanding of the stress response mechanisms have increased, a plethora of genes could have been selected as molecular markers for identifying robust probiotic strains. However, this approach has not been followed yet for a number of reasons. A closer look at the lists of genes involved in stress resistance reveals that many of them are well conserved and thus their presence does not reveal anything for the strain under investigation (e.g., heat shock proteins, F~1~F~0~-ATPase, etc.). In fact, several of them are housekeeping genes involved in central cellular processes and thus it is unlikely that they will be missing from the bacterial genome. In such cases it is the enzymatic activity of the relevant protein or protein complex that is decisive and it needs to be experimentally confirmed. For example a bile-resistant mutant of *Bifidobacterium lactis* subsp. *animalis* overexpessing the F~1~F~0~-ATPase resisted acid stress better than the parental strain ([@B241]). Finally, at this stage, very few genes could be directly related to the robustness to a specific stress. The presence of BSHs genes as an example, is indicative for resistance to bile stress. However, this information on its own is not sufficient to provide us with the overall behavior of a strain under the multitude of probiotic stresses. The identification of more sequences, linked to their respective specific phenotypes, may lead to the construction of databases with a more predictive value.

ADHESION TO THE HOST
--------------------

As discussed above, adhesion to the host's cells could be a significant characteristic of probiotics. Temporary colonization may be necessary for the probiotic to exert its properties e.g., the competitive exclusion of pathogens and the modulation of the immune system. A potential mechanism for adhesion to the host implicates the binding of molecules exposed on the surface of microbial cells to the mucus layer of the host's intestine. Mucus-binding proteins (Mubs) hold an important role in the process of probiotics' adherence to the host. Mubs are cell-surface proteins, characterized by the presence of a *C*-terminal cell wall anchoring motif (LPXTG) and multiple Mub repeats, homologous to the MucBP domains ([@B19]) which bind to mucins and glycans. Several *mub* genes and Mub proteins have been determined in probiotic strains ([@B10]; [@B182]; [@B292]; [@B269]). Surface (S-) layer proteins also play a pivotal role in the adhesion of probiotics. The *slpA* gene encoding the surface-layer protein A (SlpA) has been shown to be involved strongly in adhesion capacity ([@B8]; [@B16]; [@B269]) and has been also identified in the genome of probiotic propionibacteria ([@B79]). Some probiotic strains which are devoid of S-layer proteins, encode the aggregation promoting factor (Apf) which shares several features with the S-layer proteins ([@B282]; [@B269]). Additionally, sortase-dependent surface proteins may also play an important role concerning the adhesion to the host. It has been demonstrated that disruption of the housekeeping sortase gene *srtA* led to reduced bacterial adhesion to epithelial cells ([@B206]). A major target for bacterial adhesins is fibronectin, an extracellular matrix glycoprotein. A transcriptomics study revealed that the gene encoding a fibronectin-binding protein was significantly up-regulated during incubation in duodenal juice and bile ([@B292]). Genome analysis of a probiotic strain showed that the presence of FbpA protein may be responsible for adhesion to the extracellular matrix of epithelial cells ([@B10]). In a recent study, [@B281] demonstrated that the moonlighting protein E1 β-subunit of the pyruvate dehydrogenase complex, which is encoded by the *pdhB* gene, is an element related to fibronectin-binding. Some probiotic strains are equipped with proteinaceous surface appendages, such as pili or fimbriae, which facilitate their adhesion to human gut cells. In Gram positive bacteria the assembly of pili relies mostly upon a sortase-dependent mechanism ([@B185]). Gene clusters responsible for the biosynthesis of pili have been identified in the genomes of probiotic lactobacilli (e.g., *spaCBA*, *spaFED*; [@B138]; [@B67]) and bifidobacteria (e.g., *pil2*, *pil3, fim1, fim2, fim3*; [@B101]; [@B293]; [@B273]). Moreover, genetic analysis of several probiotic bifidobacteria strains revealed the existence of pilus gene clusters in their genome. Each cluster was organized in an operon and contained the major pilin subunit-encoding gene (*fimA* or *fimP*) along with one or two minor pilin subunit-encoding genes (*fimB* and/or *fimQ*) and a gene encoding a sortase enzyme (*strA*; [@B91]). Genes involved in the assembly of the tide adherence (Tad) pilus found in bifidobacteria has also been reported ([@B293]). Proteomic and genomic analyses have shown that moonlighting proteins (e.g., ENO, GAPDH, EF-Tu) and proteins related to stress response (e.g., DnaK, GrpE, GroEL, GroES) promote the adhesion of probiotics ([@B239]; [@B31]; [@B129]; [@B101]; [@B269]; [@B174]).

In contrast to stress related genes, genes involved in adhesion may be more informative about the properties of a strain. The presence of genes encoding adhesive molecules is still considered beneficial for selecting a probiotic strain as it might increase its interaction with the host. The adhesion biology of bacteria (both probiotics and pathogens) is a field evolving fast and detailed molecular mechanisms are being elucidated. These developments are expected to significantly improve the selection of probiotic strains. For example *in silico* analysis of these molecules may help to determine the nature of the adhesion sites (e.g., binding to fibronectin, mucin, etc.). Validation of the predicted adhesive potential of a strain is relatively straightforward with *in vitro* and *in vivo* assays as described earlier.

HUMAN MILK OLIGOSACCHARIDES AND MUCUS DEGRADATION
-------------------------------------------------

Mucins can modulate bacterial colonization as a direct energy source ([@B66]). The gene pool of bifidobacteria contains several genes involved in the metabolism of human milk oligosaccharides (HMOs) and host-derived carbohydrates, like mucins. These genes allow the adaptation of these bacteria to the human GIT ([@B221]; [@B62]). Genomic analysis of several bifidobacterial strains has given useful insights about the molecular mechanisms supporting these processes.

The genome sequence of *B. longum* subsp. *infantis* ATCC 15697 was found to contain a novel 43 kbp gene cluster encoding genes predicted to be involved in the catabolism of HMOs ([@B248]) as well as a great number of solute binding proteins (F1SBPs). The latter are part of ABC transporters and they are associated with the import of oligosaccharides. Furthermore, the expression of specific binding proteins related to HMO isomers import was induced under growth on HMO ([@B99]). It was also shown that this probiotic bacterium uses two different β-galactosidases for the degradations of type-1 and type-2 HMOs ([@B300]; [@B62]). Furthermore, in the genome sequence of *B. animalis* subsp. *lactis* AD011, several glycosylases were identified which are associated with the degradation of HMOs ([@B147]). Proteomic analysis of *B. bifidum* PRL2010 showed that among the mucin induced proteins were a variety of glycosyl hydrolases, while transcriptional profiling led to the identification of several mucin-induced genes encoding for different components (e.g., exo-α-sialidases, fucosidases, PTS systems, ABC-type carriers, specific permeases; [@B270], [@B272]). Two *B. bifidum* strains containing *engBF* and *afcA* genes, encoding for endo-α-*N*-acetylgalactosaminidase and 1,2-α-[L]{.smallcaps}-fucosidase respectively, were able to degrade high-molecular weight porcine mucin *in vitro*. The expression of both genes was highly induced in the presence of mucin ([@B233]). Moreover, two novel α-*N*-acetylgalactosaminidases from *B. bifidum* JCM 1254 have been identified, NagBb ([@B152]) and AgnB ([@B251]). These enzymes exhibit activity against the core structures in mucin O-glycans. Concerning the probiotic lactobacilli, proteomic analysis of *Lactobacillus fermentum* I5007 after exposure to jejunal environment *in vivo*, disclosed the induction of a glycoside hydrolase, a mucin degrading enzyme ([@B299]).

In addition, mucins play a crucial role in the protection of the intestinal barrier function. Mucin degradation by intestinal bacteria and its use as a carbon source stimulate goblet cells to increase mucus production. Probiotics may also influence the production of mucin directly during adhesion or through other mechanisms. A mutant of the probiotic *L. plantarum* 299v strain lacking the adhesion gene (*adh*), lost the potential to induce mucin secretion ([@B181]). A recent study demonstrated that the soluble protein p40 from the probiotic strain *L. rhamnosus* GG, stimulates the activation of epidermal growth factor receptor (EGFR), which promotes the up-regulation of mucin production in goblet cells. Therefore p40 may contribute to the protective mechanism of the intestinal epithelium from injury and inflammation ([@B290]).

The ability of probiotics to degrade hosts glycans and use host oligosaccharides as an energy source is a very important property. The presence of genes whose products are involved in these processes in the genome of a strain is a clear indication about the adaptation of this particular strain to the GIT. Such strains may have a competitive advantage over other strains in prevailing and colonizing the GIT. The stimulation of mucin production by probiotics is also very interesting as it can facilitate increased binding sites for probiotics and improved gut barrier functions.

MODULATION OF THE IMMUNE SYSTEM
-------------------------------

Probiotic bacteria can modulate the response of the host's immune system, interacting with IECs and DCs. It was demonstrated that the p40 and p75 proteins, purified from *L. rhamnosus* GG, stimulate activation of protein kinase B (Akt), promote cell growth, and inhibit TNF-α ([@B298]). Homologues of these proteins have been also found in several *L. casei* strains ([@B298]; [@B15]). The study on the extracellular proteome of *B. animalis* subsp. *lactis* BB-12 revealed six proteins with potential immunogenic effect (e.g., ClpB and Rpf; [@B101]). In *L. plantarum* strains, six genetic loci were determined with potential impact on the production of the cytokines IL-10 and IL-12 by PBMCs. These loci included genes which might induce anti- or pro-inflammatory immune responses in the intestine ([@B279]). Genetic loci that might regulate the immune response of DCs were also identified in *L. plantarum* WCFS1 ([@B194]). SlpA has been shown to induce IL-10 production in DCs ([@B154]) and to intensify immune protection by conferring resistance to infection by *Salmonella enterica* serovar Typhimurium FP1 ([@B16]). Moreover, proteomic analysis of the surface proteins of *Propionibacterium freudenreichii* ITG P20 strain revealed that several SLPs (e.g., InlA, LspA, SlpE, SlpA, SlpB) are contributing factors in the induction of the IL-10 and IL-6 regulatory cytokines ([@B174]).

Serine protease inhibitor (serpin)-encoding genes (*ser*) are found in several bifidobacteria and they are involved in the inhibition of elastases, components related to intestinal inflammation ([@B271]). It has also been shown that *B. breve* UCC2003 produces a cell surface-associated EPS, encoded by each half of a bidirectional gene cluster, which evokes a weak adaptive immune response and it provides protection against the gut pathogen *Citrobacter rodentium* ([@B80]).

Defensins are inducible antimicrobial peptides of the innate immune system, which play an important role in host defenses ([@B97]). It has been demonstrated that the protein flagellin, produced by the probiotic strain *E. coli* Nissle 1917, induces the expression of human β-defensin 2 (hBD-2) by the intestinal epithelium ([@B246]). Mutants devoid of the gene responsible for the production of flagellin, presented decreased ability to induce hBD-2.

Our understanding of the mechanisms involved in the modulation of the host's immune responses by probiotics is far from complete. Even though several genetic and omics studies have shed some light on the relevant mechanisms there is much ground to be covered. Novel developments in meta-transcriptomics and meta-proteomics are expected to speed up research in this field since they will allow the direct study of the interactions between microorganisms and the cell of the host. Currently, it is very difficult to determine *a priori* whether a strain could modulate immune responses (beneficial or not), based solely on sequence data. This is the main reason making it necessary to assess immunomodulatory properties during screening for probiotics with *in vitro* and/or *in vivo* tests.

PRODUCTION OF ANTIMICROBIAL COMPOUNDS
-------------------------------------

Probiotic strains often produce an array of antimicrobial compounds. Several of these, like organic acids (e.g., lactic acid) are primary metabolites. In most of these cases, the molecular players of these metabolic pathways for those molecules have been well studied. Other antimicrobial compounds are secondary metabolites, like bacteriocins. The biosynthetic regulons of many bacteriocins have been described and their mode of action has been elucidated. The beneficial effect of bacteriocin-producing probiotic strains against invasive enteropathogens has been well established *in vivo*. It has been demonstrated that the bacteriocin Abp118, produced by *L. salivarius* UCC118, was active against *Li*s*teria monocytogenes* in mice ([@B56]). High throughput sequencing of bacterial genomes allows the rapid identification of genetic loci related to bacteriocin production and/or immunity. However, bacteriocins should not strictly be considered as antimicrobials. For example it has been demonstrated that six genes of *L. plantarum* WCFS1 associated with the plantaricin biosynthesis and secretion, regulated the production of pro- and anti-inflammatory cytokines of DCs ([@B194]).

QUORUM SENSING
--------------

QS is a communication mechanism among bacterial cells which allows the orchestrated expression of genes within bacterial populations. Its function relies on signaling molecules known as autoinducers. In Gram negative bacteria QS signaling relies on *N*-acylhomoserine lactones (AHL), while in Gram positive bacteria this procedure is dependent upon small cyclic and linear peptides ([@B291]).

In *L. plantarum* WCFS1 genome an *agr*-like two component regulatory system, encoded by the *lamBDCA* operon, was identified. This operon contained four genes encoding an autoinducing signaling peptide (AIP) modification protein (*lamB*), an AIP (*lamD*), a membrane-located histidine protein kinase (*lamC*) and a cytoplasmic response regulator (*lamA*). This system encodes for a cyclic thiolactone autoinducing peptide (CVGIW) which regulates the adhesion capability of the strain ([@B259]). The same strain was shown to carry a second *agr*-like QS system encoded by the *lamKR* operon, which was similar to the *lamBDCA* operon, suggesting analogous function ([@B92]). The probiotic strain *E. coli* Nissle 1917 was shown to produce AI-2 molecules (e.g., furanosyl borate diester), involving the *luxS* (autoinducer) gene expression. These molecules were found to influence the induction of anti-inflammatory cytokines in a mouse model of acute colitis ([@B130]). In *L. acidophilus* NCFM, the transcription of the *luxS* gene was notably increased after co-cultivation with live *Listeria monocytogenes* cells, indicating the important role of signaling molecules to the adhesion and the competitive exclusion of pathogens in the GIT ([@B28]; [@B204]). *B. animalis* subsp. *lactis* BB-12 produces a QS system related peptide (CHWPR). It has been demonstrated that this peptide enhances the expression of two genes in somatic cells, the gene *c-myc*, the deregulation of which has been associated with several forms of cancer, and IL-6, an anti- and pro-inflammatory cytokine ([@B199]). The role of AI-2 signaling molecule to the adhesive potential of probiotic lactobacilli has also been addressed. It has been established that the disruption of the *luxS* gene reduced significantly the adherence to IECs ([@B28]).

QS is a very important aspect that may dramatically affect the efficacy of probiotics *in vivo*. Probiotics are entering an already established microbiome, including established biofilms, in which they need to be incorporated. In such an ecological system inter- and intra-species communication is vital to secure temporary colonization of the host, release of antimicrobial compounds and competitive exclusion of pathogens. Evidently, there is an ongoing communication between the microbiome (including any probiotic strain present) and the cells of the host, perhaps beyond immunomodulation. Detailed knowledge about these phenomena may allow us to optimize the probiotic effect.

PRODUCTION OF NUTRIENTS AND OTHER BENEFICIAL PROCESSES
------------------------------------------------------

Production of nutrients in the GIT by probiotic bacteria is an essential process for both the host and the microbiome. *In silico* genome analysis of two *L. reuteri* strains revealed genes responsible for the production of vitamins, essential amino acids, lactate and SCFA ([@B244]). It was shown that both strains hold complete biosynthetic pathways for folate and vitamin B12 and that one of the strains carried also a pathway for the production of vitamin B1. Analysis of the *P. freudenreichii* CIRM-BIA1^T^ genome revealed genes associated with the production of SCFAs and the precursor of menaquinone (vitamin K2), a bifidogenic compound ([@B79]). The *fos* gene cluster of *B. animalis* subsp. *lactis* AD011 is another bifidogenic agent, since it is implicated in the processing of health-promoting fructooligosaccharides ([@B147]). This cluster was shown to have high similarity to the relevant operon described for *B. breve* UCC2003 ([@B236]). Furthermore, probiotic bacteria appear to hold a significant role in the modulation of nutrient absorption and in the regulation of the host's energy balance. Several bifidobacteria possess genes encoding for ABC carbohydrate transporters. The latter contribute to the high consumption rate of specific carbohydrates resulting in high production of acetate, a metabolite which confers protection from enteropathogenic infection ([@B94]). Furthermore, genetic and proteomic analysis of *L. acidophilus* A4 revealed that the catabolite control protein A (*ccpA*) is probably involved in the reduction of total serum cholesterol by influencing the expression of several membrane associated proteins. These proteins may play a role in the adhesion of the cholesterol to the bacterial cells and consequently, in the process of lowering blood cholesterol ([@B170]).

FUTURE PERSPECTIVES FOR THE USE OF OMICS IN PROBIOTIC RESEARCH
--------------------------------------------------------------

Several aspects of the molecular mechanisms that underpin probiotic properties have been elucidated. Original studies relied on molecular analysis of single genes and proteins. Over the last decade the advent of omics technologies have allowed the study of probiotic organisms at the whole genome level ([@B108]). Today, metagenomics methodologies are revealing the composition of complex ecosystems and their biology ([@B225]; [@B275]). All niches of the human body carry microbiomes that diverge according to the specific compartment, the age and the dietary habits of the individual and many other factors ([@B227]). Meta-omics offer for the first time the proper tools for understanding the *in vivo* behavior of probiotics in contrast to simulated conditions involving pure or only a handful of microbial cultures. As omics technologies become cheaper the genome sequencing of microorganisms will become a routine practice. Incorporation of novel functional data through high throughput transcriptomics and proteomics into databases will ultimately facilitate the *in silico* assessment of the probiotic potential of candidate microorganisms. It is too early to speculate whether *in silico* analysis will totally abolish experimental approaches. It is certain though that as our understanding of the molecular biology of probiotic properties improves, we will be able to design more efficient and more sophisticated *in vitro* and *in vivo* tests. Finally the cataloging of the human microbiome has already opened up the door for considering new categories of microorganisms as potential probiotics beyond the usual suspects (i.e., LAB and bifidobacteria).

CONCLUSION
==========

In this review we presented a detailed overview of the different methodologies employed for the discovery of new probiotic strains. The diversity of screening assays is considerable and their efficacy variable. Some assays are more applicable for screening high numbers of strains while others are more appropriate for validating the probiotic properties of a handful of strains. There is no bulletproof procedure or workflow for selecting probiotics than perhaps the actual testing of candidate strains on the target population ([@B231]). However, considering the limitations of human trials, traditional *in vitro* and *in vivo* assays along with novel omics approaches will remain important. To take full advantage of probiotics for the health of humans a methodological evolution is needed. For example, new "humanized" animal models may be necessary to study host--microbe interactions. Such developments need to go hand in hand with improvements in legislation, ethics, if we want to meet the scientific and technological challenges of probiotic research.

Today, in most parts of the Western world, the acceptance of health claim dossiers is very difficult. In Europe the use of the term "probiotic" has been banned in communications toward the consumer. In the food area, except for a health claim on lactose tolerance for yogurt, none of the 300 bundled health claim dossiers have been approved. It can be hoped that a more profound study of the mechanisms of action and a better understanding of the microbiome functioning and its dynamics with the host, will provide the health claim evaluation panels with the necessary evidence to consider a wider legal acceptance of health claims. While some of the technological evolutions mentioned in this review have the potential to contribute significantly to this, the willingness to consider new types of probiotics, such as *F. prausnitzii* or *A. muciniphila*, currently not yet available on the market, will be crucial.

Not treated in this review is the importance of the production process. With these new, highly anaerobic organisms such as *F. prausnitzii* or *A. muciniphila* in mind, it will be important for probiotic producers to come up with new production processes and modified preservation and administration strategies to guarantee the delivery of active strains to the consumer or patient. As several papers have shown ([@B276]; [@B167], [@B166]; [@B27]; [@B277]) the (industrial) processing of a probiotic preparation has a fundamental impact on the functionality in the host. Viability, the presence or absence of pili, the cell wall condition, the matrix or the growth stage of the probiotic, they all seem to have an important influence on its performance and its interaction with the host. Defining the mechanism of action of a probiotic might therefore also include some critical parameters of the production process.

Without any doubt, the continued development of omics technologies will assist in alleviating the shortages currently faced with the traditional *in vitro* and *in vivo* models. Although it may take a while before we can predict probiotic functionality directly from genomic and metagenomic information, the use of omics approaches to follow up on interesting *in vitro* or *in vivo* observations is very likely going to speed up research progress in the field of probiotics in the near future.
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